Melola Discovery

← Melola Discovery

Open access Journal SINTA 1

THE USE OF HYDROXYETHYL STARCH 200/0,5 AS PLASMA SUBTITUTES IS SAFE IN HYPOVOLEMIC PATIENTS AS INDICATED IN CHANGES OF N-ACETYL--GLUCOSAMINIDASE AND CREATININ SERUM PARAMETERS

Folia Medica Indonesiana · Vol. 51 No. 4 (2016) · pp. 228–228

DOI
10.20473/fmi.v51i4.2852
ISSN
2355-8393, 2599-056X
Published
2016-11-15
Publisher
Airlangga University
Language
en
License
creativecommons.org/licenses/by-nc-sa/4.0/

Abstract

Hydroxyethyl Starch (HES) is a compound that improves intravascular volume effectively and rapidly without causing tissue edema. However, HES also has renal safety profile which is still being debated. Based on clinical experience in Dr. Soetomo Hospital, the frequency of acute renal failure following HES 200/0.5 administration at a dose of less than 20 ml/kg (maximum dose) is very rare. The purpose of this study was to evaluate the effect of HES 200/0.5 at a dose of less than 20 ml/kg in patients undergoing surgery. N-acetyl-b-D-Glucosaminidase (NAG) per urine creatinine ratio and creatinine serum were used as main parameter to assess renal injury. This research was observational and prospective design in patients undergoing elective surgery at Gedung Bedah Pusat Terpadu, Dr. Soetomo Hospital, who requiring resuscitation therapy with HES 200/0.5 and met the inclusion and exclusion criteria. NAG was measured prior to surgery and 12 hours after administration of fluid therapy, while creatinine serum was observed before surgery and 48 hours after resuscitation. This study was conducted for three months, and obtained 50 subjects divided into 2 groups, crystalloid group and HES 200/0.5 group. Demographic and baseline characteristics did not differ between groups, except the total bleeding volume. Total bleeding in HES 200/0.5group was higher than crystalloid group (p <0.0001). The mean volume of fluid received in HES 200/0.5 group was 2042.0 ± 673.9 mL, higher when compared with that of crystalloid group (910.0 ± 592.0 ml). Doses of HES 200/0.5 received was 8.31 ± 4.86 ml/kg. Measurement of the of NAG/creatinine ratio and creatinine serum showed significant increase in both groups, but still within the normal range. In addition, the value of these two parameters did not differ between groups. In conclusion, HES 200/0.5 in a dose of less than 20 ml/kg is safe to use in patients who suffered from hypovolemic hemorrhage, without prior history of renal impairment.

Keywords

Collaboration network of the authors

40 authors · 94 co-authorship links · 23 across different organisations · showing the 40 most connected

Hover or tap a name to highlight its co-authors. Double-click to open the author's page.

  • Universitas Airlangga
  • Lambung Mangkurat University
  • State University of Makassar
  • University of Brawijaya
  • Joseph Sarwuan Tarka University Makurdi
  • Tadulako University
  • Affiliation unknown
  • Different organisations
  • Same organisation
  • Affiliation unknown
  • Thicker line = more joint articles · bigger circle = more articles
Show as table
Co-authorOrganisationJoint articles
Imam SusiloUniversitas Airlangga5
Sarah Puspita AtmajaUniversitas Airlangga5
Ika Ayu MentariUniversitas Airlangga2
Rifda NaufalinaUniversitas Airlangga2
Selvi MegawatiUniversitas Airlangga2
Yuyun WirasasmitaTadulako University2
Rifda Naufa LinaUniversitas Airlangga2
Suharjono SuharjonoUniversity of Brawijaya1
Muhammad Darwin PrenggonoLambung Mangkurat University1
Ratih Pratiwi SariUniversitas Airlangga1
Aditya Maulana Perdana PutraLambung Mangkurat University1
Andi Bulqiah NurState University of Makassar1
Moch YusufUniversitas Airlangga1
YulistianiUniversitas Airlangga1
Wulida Nuril FajriyahState University of Makassar1
Zam Zami JauhariUniversitas Airlangga1
Diyah WahyuniUniversitas Airlangga1
Ramadi Satryo WicaksonoAffiliation unknown1
Abdul Kadir JaelaniAffiliation unknown1
Vini Siane TanaemUniversitas Airlangga1
Endang Dewi MasithahUniversitas Airlangga1
Aondohemba Samuel NegeJoseph Sarwuan Tarka University Makurdi1
Cantika Suci Adlina LasandaraUniversitas Airlangga1
Samirah SamirahUniversitas Airlangga1
Aniek Setiya BudiatinUniversitas Airlangga1
Anak Agung Ngurah Putra Riana PrasetyaUniversitas Airlangga1
Bayu Dharma ShantiAffiliation unknown1
Dewi Perwito SariUniversitas Airlangga1
Yulistiani YulistianiUniversitas Airlangga1
Mida PurwiningtyasUniversitas Airlangga1
Bayu Dharma SantiAffiliation unknown1
Dwi Hari SusiloUniversitas Airlangga1
Ria Fitrah ArfianiUniversitas Airlangga1
Agung Dwi Wahyu WidodoUniversitas Airlangga1
Muhammad Thariq NadhafiAffiliation unknown1

Affiliations come from OpenAlex; journal OAI-PMH metadata carries none. Authors without an OpenAlex ID are matched by name, which can merge or split people.

Metadata source: OpenAlex API (jurnal SINTA, ADR 0048) https://openalex.org/S4210179714, first harvested 19 Nov 2026, last seen 19 Nov 2026.
Original metadata (oai_dc)
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/"><dc:title xml:lang="en">THE USE OF HYDROXYETHYL STARCH 200/0,5 AS PLASMA SUBTITUTES IS SAFE IN HYPOVOLEMIC PATIENTS AS INDICATED IN CHANGES OF N-ACETYL--GLUCOSAMINIDASE AND CREATININ SERUM PARAMETERS</dc:title><dc:creator>Dewi Wara Shinta</dc:creator><dc:creator>Junaidi Khotib</dc:creator><dc:creator>Eddy Rahardjo</dc:creator><dc:creator>Mahardian Rahmadi</dc:creator><dc:creator>Budi Suprapti</dc:creator><dc:subject>hydroxyethyl starch 200/0.5</dc:subject><dc:subject>plasma expanders</dc:subject><dc:subject>acute kidney injury</dc:subject><dc:subject>N-acetyl-beta-D-glucosaminidase</dc:subject><dc:subject>serum creatinine</dc:subject><dc:subject>crystalloid fluid therapy</dc:subject><dc:subject>fluid resuscitation</dc:subject><dc:subject>elective surgery</dc:subject><dc:subject>renal safety</dc:subject><dc:subject>blood loss</dc:subject><dc:subject>tissue edema</dc:subject><dc:subject>hemodilution</dc:subject><dc:description xml:lang="en">Hydroxyethyl Starch (HES) is a compound that improves intravascular volume effectively and rapidly without causing tissue edema. However, HES also has renal safety profile which is still being debated. Based on clinical experience in Dr. Soetomo Hospital, the frequency of acute renal failure following HES 200/0.5 administration at a dose of less than 20 ml/kg (maximum dose) is very rare. The purpose of this study was to evaluate the effect of HES 200/0.5 at a dose of less than 20 ml/kg in patients undergoing surgery. N-acetyl-b-D-Glucosaminidase (NAG) per urine creatinine ratio and creatinine serum were used as main parameter to assess renal injury. This research was observational and prospective design in patients undergoing elective surgery at Gedung Bedah Pusat Terpadu, Dr. Soetomo Hospital, who requiring resuscitation therapy with HES 200/0.5 and met the inclusion and exclusion criteria. NAG was measured prior to surgery and 12 hours after administration of fluid therapy, while creatinine serum was observed before surgery and 48 hours after resuscitation. This study was conducted for three months, and obtained 50 subjects divided into 2 groups, crystalloid group and HES 200/0.5 group. Demographic and baseline characteristics did not differ between groups, except the total bleeding volume. Total bleeding in HES 200/0.5group was higher than crystalloid group (p &lt;0.0001). The mean volume of fluid received in HES 200/0.5 group was 2042.0 ± 673.9 mL, higher when compared with that of crystalloid group (910.0 ± 592.0 ml). Doses of HES 200/0.5 received was 8.31 ± 4.86 ml/kg. Measurement of the of NAG/creatinine ratio and creatinine serum showed significant increase in both groups, but still within the normal range. In addition, the value of these two parameters did not differ between groups. In conclusion, HES 200/0.5 in a dose of less than 20 ml/kg is safe to use in patients who suffered from hypovolemic hemorrhage, without prior history of renal impairment.</dc:description><dc:publisher>Airlangga University</dc:publisher><dc:date>2016-11-15</dc:date><dc:type>info:eu-repo/semantics/article</dc:type><dc:format>application/pdf</dc:format><dc:identifier>https://doi.org/10.20473/fmi.v51i4.2852</dc:identifier><dc:identifier>10.20473/fmi.v51i4.2852</dc:identifier><dc:source>Folia Medica Indonesiana; Vol 51 No 4 (2016); 228-228</dc:source><dc:source>2355-8393</dc:source><dc:source>2599-056X</dc:source><dc:language>en</dc:language><dc:relation>https://e-journal.unair.ac.id/FMI/article/download/2852/2065</dc:relation><dc:rights>https://creativecommons.org/licenses/by-nc-sa/4.0/</dc:rights></oai_dc:dc>